Verge Genomics

Verge Genomics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.vergegenomics.com

Last Round

Series B

Dec 16, 2021

Est. Valuation

$1.71M

Total Funding Raised

$134.12M

Company Overview

Verge Genomics is a biotechnology company that offers a drug discovery platform designed to expedite the creation of life-saving treatments for neurodegenerative diseases through machine learning and data analysis.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

AI drug discoveryneurodegenerative diseasedrug discovery platformtechbiohuman data drug discoveryclinical-stage biotechmulti-omics platformALS treatmentdrug target identificationprecision medicineParkinson's diseasepharma partnershipsdrug licensingmetabolic disease therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Verge Genomics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Verge Genomics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BDec 16, 2021
Series AJul 16, 2018
SeedNov 3, 2015
AcceleratorJul 21, 2015

Key People

Founding team and executive leadership

Alice Zhang

CEO Co-founder

Founding Team

Verge Genomics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 23, 2026

    Eli Lilly and AstraZeneca partnerships exceed $1.6B.

  • Feb 23, 2026

    Two unnamed drugs have been delivered to the clinic.

Verge Genomics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Verge Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Verge Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range29
Year Founded2015
Last FundingDec 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.